Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

A, Woolloongabba N Clinical Trials

A listing of A, Woolloongabba N clinical trials actively recruiting patients volunteers.


Found (116) clinical trials

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neo adjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.


Phase 2 Trial in Multiple Brain Metastases Comparing HA-WBRT and HA-SIB-WBRT Outcomes

Recently, the evidence supports hippocampal avoidance with whole brain radiotherapy (HA-WBRT) as the recommended treatment option in patients with good prognosis and multiple brain metastases as it gives better neurocognitive preservation compared to historical whole brain radiotherapy controls. There is however often poor tumour control with this technique due to …


Histopathologic Effect of Calcium Electroporation on Cancer in the Skin

In this non randomized phase II study, we will explore histopathological tumour cell death mechanisms in 12 patients with breast cancer metastases and 12 patients with other cutaneous or subcutaneous malignancy. The primary endpoint of the biopsy study is to evaluate differences in tumour infiltrating lymphocyte (TIL) population in tissue …


Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

PRIMARY OBJECTIVE: I. To assess pneumonitis response to additional immunosuppression (infliximab or intravenous immunoglobulin therapy [IVIG]) in patients with steroid-refractory pneumonitis at 28-days. SECONDARY OBJECTIVES: I. To assess functional parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG). …


A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.


Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.


A Study of LY3819253 (LY-CoV555) in Participants With Early Mild to Moderate COVID-19 Illness

The purpose of this study is to measure how well LY3819253 works against the virus that causes COVID-19. LY3819253 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus …


A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy Irinotecan Plus Platinum and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer SCLC

This single arm, open label, single center, prospective study was designed to evaluate the safety and efficacy of Sequential Therapy of Camrelizumab (humanized monoclonal antibody against Programmed death 1 [PD-1] ) in combination with ChemotherapyIrinotecan plus Platinumand with Apatinib (selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor [TKI]) …


Vigamox Treatment for Ocular Graft-Versus-Host Disease

In this study the investigators seek to prospectively measure the response of ocular graft-versus-host disease (GVHD) patients to treatment with topical Vigamox. The investigators will accomplish this by enrolling patients with bilateral ocular GVHD and treating one eye with topical Vigamox and the other eye with a placebo eye drop. …


Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

This trial investigates the feasibility and treatment efficacy when combining durvalumab treatment with either conventionally fractionated (CON-group) or hypofractionated thoracic radiotherapy (HYPO-group) in previously untreated NSCLC stage III patients prone to radiotherapy only. A safety lead-in phase with stop-and-go design will precede full enrollment into the HYPO-group. Tumor tissue as …